Analysed ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) News Sources
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
20-04-2026
yahoo.com
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
29-04-2026
yahoo.com
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
04-05-2026
yahoo.com
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
12-05-2026
yahoo.com
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
19-05-2026
yahoo.com
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
16-06-2026
yahoo.com
What is the current price of ACURX PHARMACEUTICALS INC (ACXP:NASDAQ)?
The current price of ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) is $1.5.
ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) since the previous trading day is $0.04.
ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) since the previous trading day is 2.7397%.
What is the most recent average sentiment score for ACURX PHARMACEUTICALS INC (ACXP:NASDAQ)?
The most recent average sentiment score for ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for ACURX PHARMACEUTICALS INC (ACXP:NASDAQ)?
The most recent sentiment for ACURX PHARMACEUTICALS INC (ACXP:NASDAQ) is .
SEC-8K** Filing Available For ACURX PHARMACEUTICALS INC (ACXP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.